Pinealon Research

Pinealon is a synthetic tripeptide, sequence Glu-Asp-Arg or EDR ^[1], and it belongs to a group of short peptides developed in Russia and marketed as peptide bioregulators. This page summarizes what has been published about Pinealon, and what has not.

Identity and naming

The name is misleading, because pinealon is not a pineal gland extract and was not isolated from one. The US National Library of Medicine indexes it under the entry terms pinealon, T-33 peptide and Glu-Asp-Arg, calling it a synthetic tripeptide ^[1].

PubChem holds it as CID 10273502, molecular formula C15H26N6O8, and the registry number 175175-23-2 resolves to that same record on a direct re-check.

One research group produced almost all of this literature

Vladimir Khavinson and the St Petersburg Institute of Bioregulation and Gerontology discovered these peptides, hold patents covering them, and sell them. The same people produced nearly all of the research, wrote the only indexed systematic review of the family ^[2], and declared no conflict of interest on it.

Khavinson is an author on 497 PubMed records, about 65 percent Russian-language, with 42 percent in two journals; a PubMed search for pinealon returned 22 records in August 2026 ^[11]. This is not an independent evidence base.

How pinealon relates to its siblings

These compounds are nested sub-sequences of one another. The developer's family table lists EDR alongside three tripeptides differing from it by one residue, and the four-residue members add a front alanine ^[13]. No published study explains what functionally distinguishes pinealon from a sibling differing by one residue, and the literature is silent there.

Longevity and mortality figures circulating for "Khavinson peptides" belong to other substances, including crude bovine extracts that are not pinealon.

What has been reported in vitro

The developer group's stated mechanism is that short peptides enter the nucleus and bind DNA and histones, recognizing sequences in gene promoters and changing gene expression ^[2]. Three in vitro studies name EDR directly, and only one of them used cells.

In that one, fluorescein-tagged EDR added to HeLa cells produced fluorescence in cytoplasm, nucleus and nucleolus ^[1]. That is weak evidence for nuclear entry by the untagged peptide. Fluorescein roughly doubles the mass of a three-residue peptide, is membrane-permeant, and accumulates in nucleoli itself. No measurement of unlabeled EDR inside a cell has been published.

The second is a cell-free binding assay, reporting EDR among six peptides binding fluorescein-labeled wheat histones ^[3]. That is a plant protein system, read indirectly. It also cuts against the DNA-binding half of the stated mechanism, since histone binding would explain gene-expression effects without sequence-specific DNA contact.

The third is the most technically serious: a 2019 study in The Journal of Physical Chemistry B examined EDR with DNA in solution, again without cells ^[4]. It used spectral methods, NMR, viscosimetry and molecular dynamics, and reported partial major-groove penetration at guanine N7 and O6. Khavinson is not an author, but the senior author has co-authored with him before. Call it semi-independent, not arm's length.

It is the only NMR study indexed in this family, and should not be over-read: guanine N7 is a generic contact point for many small molecules ^[11]. Across the family there is still no deposited structure, no dissociation constant, no SELEX motif and no in-cell promoter occupancy data ^[11].

What has been reported in animals

In a mouse model of Alzheimer's disease, EDR and a second tripeptide were reported to prevent loss of dendritic spines ^[5]. This is an animal finding and says nothing about people. The mechanism was assigned by docking, not a binding measurement, and the paper carries a published correction stating that two figures were the same image described as different experiments ^[5].

A Russian-language report gave short peptides to old rats before carotid artery occlusion and reported improved survival ^[6]. Pinealon was compared against Cortexin, a separate preparation, in parallel arms rather than co-administered with it. The survival statement is attributed generically to short peptides, with no per-compound figure, so nothing there is attributable to pinealon alone, and only an English abstract exists.

No lifespan or longevity study of pinealon in any species is indexed ^[11].

What has been reported in people

Three Russian-language reports in Advances in Gerontology are the entire human record for pinealon. None is randomized, controlled, blinded or registered, and no trial of pinealon appears on ClinicalTrials.gov ^[11].

The first describes locomotive crew workers, reporting improved biological age and adaptive reaction indicators ^[7]. PubMed assigns it no clinical trial type, and the abstract gives no sample size or control group.

The second studied 32 people aged 41 to 83 with chronic conditions and organic brain syndrome in remission ^[8]. It reports improved central nervous system activity, and says a second tripeptide tested alongside EDR had the more visible effect. The same abstract reports prooxidant activity by chemiluminescence, and a fall in circulating CD34-positive cells the authors call significant inhibition of hemopoiesis ^[8]. That is a human adverse signal from the developer network's own literature, rarely quoted.

The third used a Work Ability Index in Russian lorry drivers, with pinealon among the peptides indexed ^[9]. It discusses combined peptide use only, so nothing can be attributed to pinealon.

Absorption, pharmacokinetics and safety

No human pharmacokinetic data has been published for pinealon, and no plasma concentration, half-life or clearance figure has been reported.

Pinealon is a tripeptide, so it is the right size for PepT1, the gut transporter that carries di- and tripeptides ^[12]. That is an inference from transporter biology, not an experiment. Nobody has tested pinealon as a substrate, and transport is not systemic delivery. One 2023 paper modeled EDR transport by PEPT1 and the LAT carriers, but it was docking only ^[10].

No formal toxicology package has been published for pinealon: no dose-ranging, repeat-dose, genotoxicity or carcinogenicity study. The only safety statement specific to pinealon is one line in the 32-patient report asserting chromatin condensation was unaffected ^[8]. That study was not powered to detect harm, and the same abstract carries the findings above. Absence of published toxicology is not evidence of safety.

Conclusion

The indexed record for pinealon is small, and almost all of it comes from the group that discovered, patented and sells these peptides. Three in vitro studies, two animal reports and three Russian-language human reports are the whole of it, and none of the human work is randomized, controlled, blinded or registered. No human pharmacokinetic data or toxicology package has been published, no lifespan study is indexed, and one human report carries an adverse signal that is rarely quoted ^[8]. Pinealon is a research compound and is not for human consumption.

Frequently Asked Questions

Is there human evidence for pinealon? Three Russian-language reports mention it in people, and none is randomized, controlled, blinded or registered ^[7][8][9]. One also reports prooxidant activity and a fall in circulating CD34-positive cells the authors call significant inhibition of hemopoiesis ^[8].

Has anyone outside the developer group tested it? One 2019 biophysical study of EDR with DNA was published without Khavinson as an author ^[4]. Its senior author has co-authored with him before, so it is semi-independent. Nearly all the rest comes from the group that discovered, patented and sells these peptides ^[11].

Does pinealon come from the pineal gland? No, pinealon is not a pineal gland extract and was not isolated from one. It is a synthetic tripeptide, Glu-Asp-Arg ^[1]. The developer's family table lists three further tripeptides differing from it by one residue, and no published study explains what functionally distinguishes them ^[13].

References

1. 1

   Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Biochemistry (Moscow). 2011;76(11):1210-1219. PMID 22117547. DOI: 10.1134/S0006297911110022. (Pinealon = Glu-Asp-Arg; FITC-labeled peptides in HeLa cytoplasm, nucleus and nucleolus.) NLM supplementary concept record C570174 supplies the entry terms pinealon, T-33 peptide, Glu-Asp-Arg and the description "synthetic tripeptide".
2. 2

   Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Molecules. 2021;26(22):7053. PMID 34834147. DOI: 10.3390/molecules26227053. (Developer-authored systematic review stating the peptide-DNA hypothesis; discusses EDR by sequence code.)
3. 3

   Fedoreyeva LI, et al. Biochemistry (Moscow). 2013;78(2):166-175. PMID 23581987. DOI: 10.1134/S0006297913020053. (EDR among six peptides binding FITC-labeled wheat histones H1, H2B, H3 and H4.)
4. 4

   Silanteva IA, et al. The Journal of Physical Chemistry B. 2019;123(9):1896-1902. PMID 30762356. DOI: 10.1021/acs.jpcb.8b10359. (Role of mono- and divalent ions in Glu-Asp-Arg / DNA interaction; spectral, NMR, viscosimetry and molecular dynamics; partial major-groove penetration at guanine N7 and O6.)
5. 5

   Khavinson V, et al. Pharmaceuticals (Basel). 2021;14(6):515. PMID 34071923. DOI: 10.3390/ph14060515. Correction: Pharmaceuticals (Basel). 2025;18(1):111. PMID 39861198. DOI: 10.3390/ph18010111. (EDR and KED prevented dendritic spine loss in 5xFAD mice; mechanism assigned by docking; correction states Figures 5 and 8 were the same image described differently.)
6. 6

   Mendzheritskii AM, et al. Advances in Gerontology (Uspekhi Gerontologii). 2011;24(1):74-79. PMID 21809624. (Russian. Short peptides given before carotid artery occlusion in old rats; behavior, brain caspase-3 activity and survival.)
7. 7

   Nazimko VA, et al. Advances in Gerontology (Uspekhi Gerontologii). 2012;25(1):57-62. PMID 22708445. (Russian. Biological age parameters and adaptation indicators in locomotive crew workers; no trial publication type assigned.)
8. 8

   Meshchaninov VN, et al. Advances in Gerontology (Uspekhi Gerontologii). 2015;28(1):62-67. PMID 26390612. (Russian. 32 patients aged 41 to 83; EDR and KED; reported CNS improvement, prooxidant activity by chemiluminescence, and CD34-positive cell decrease described as inhibition of hemopoiesis.)
9. 9

   Bashkireva AS, et al. Advances in Gerontology (Uspekhi Gerontologii). 2015;28(3):510-512. PMID 28509489. (Russian. Work Ability Index in lorry drivers; pinealon indexed to the record; combined peptide use only.)
10. 10

    Khavinson VK, et al. Biomolecules. 2023;13(3):552. PMID 36979488. DOI: 10.3390/biom13030552. (Molecular modeling and docking of 26 ultrashort peptides including EDR against PEPT1, LAT1 and LAT2; no transport assay.)
11. 11

    PubMed E-utilities corpus and absence searches, and ClinicalTrials.gov API v2 query, run 27 August 2026. (Khavinson author records 497, 65 percent Russian-language, 42 percent in two journals; pinealon bare-term count 22; no lifespan or longevity record for pinealon or EDR; family names and sequence codes crossed with NMR return only PMID 30762356. plus one unrelated receptor-modeling record; no deposited structure, Kd, SELEX motif or ChIP occupancy located across the family; no registered trial for pinealon.)
12. 12

    Spanier B, Rohm F. Comprehensive Physiology. 2018;8:843-869. PMID 29687907. DOI: 10.1002/cphy.c170038. (PepT1/SLC15A1 transports di- and tripeptides.)
13. 13

    Khavinson V, et al. International Journal of Molecular Sciences. 2022;23(14):7733. PMID 35887081. DOI: 10.3390/ijms23147733. (Family sequence table listing EDR alongside three further tripeptides differing in one residue, and the corresponding alanine-extended tetrapeptides.)